Point72 Asia (Singapore) Pte. Ltd. Astria Therapeutics, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $381 Billion
- Q1 2025
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 6,715 shares of ATXS stock, worth $26,591. This represents 0.01% of its overall portfolio holdings.
Number of Shares
6,715Holding current value
$26,591% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding ATXS
# of Institutions
120Shares Held
51.1MCall Options Held
5.3KPut Options Held
6.1K-
Perceptive Advisors LLC New York, NY6.49MShares$25.7 Million1.45% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.11MShares$20.2 Million0.57% of portfolio
-
Vestal Point Capital, LP New York, NY4.18MShares$16.6 Million1.59% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.82MShares$15.1 Million4.93% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$14.1 Million6.47% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $60.1M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...